Robust leptin secretory responses to dexamethasone in obese subjects

Samuel Dagogo-Jack, Gregg Selke, Angela K. Melson, John W. Newcomer

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Although leptin reverses obesity in rodents, its function and regulation in humans are unknown. Glucocorticoids have been reported to stimulate leptin production in both rodents and humans, but data assessing the effect of obesity on dynamic leptin secretory responses are unavailable. We, therefore, studied 52 lean and obese subjects [20 men and 32 women; aged 19-84 yr; body mass index (BMI) range, 16-47 kg/m2] randomized to treatment with dexamethasone (total dose, 10 μg/4 days) or placebo. Compared with placebo, dexamethasone increased (P = 0.0001) plasma leptin levels by 64-111% above baseline values within 2-4 days. The increases occurred in all ages, showed no sexual dimorphism, and were particularly robust in obese subjects. After dexamethasone treatment, significant interactions were observed between the change in plasma leptin and BMI (P = 0.0001), baseline plasma leptin (P = 0.0006) and plasma dexamethasone levels (P = 0.04), but not age (P = 0.28); an apparent interaction with plasma insulin no longer was significant after controlling for BMI. These results confirm dexamethasone-induced hyperleptinemia in humans and further demonstrate that the response is not defective in obesity.

Original languageEnglish (US)
Pages (from-to)3230-3233
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume82
Issue number10
DOIs
StatePublished - Oct 13 1997

Fingerprint

Leptin
Dexamethasone
Plasmas
Body Mass Index
Obesity
Beam plasma interactions
Rodentia
Placebos
Sex Characteristics
Glucocorticoids
Insulin
Therapeutics

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Robust leptin secretory responses to dexamethasone in obese subjects. / Dagogo-Jack, Samuel; Selke, Gregg; Melson, Angela K.; Newcomer, John W.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 10, 13.10.1997, p. 3230-3233.

Research output: Contribution to journalArticle

Dagogo-Jack, Samuel ; Selke, Gregg ; Melson, Angela K. ; Newcomer, John W. / Robust leptin secretory responses to dexamethasone in obese subjects. In: Journal of Clinical Endocrinology and Metabolism. 1997 ; Vol. 82, No. 10. pp. 3230-3233.
@article{1173c8f4a1fe4e1d98891e0d94ab9093,
title = "Robust leptin secretory responses to dexamethasone in obese subjects",
abstract = "Although leptin reverses obesity in rodents, its function and regulation in humans are unknown. Glucocorticoids have been reported to stimulate leptin production in both rodents and humans, but data assessing the effect of obesity on dynamic leptin secretory responses are unavailable. We, therefore, studied 52 lean and obese subjects [20 men and 32 women; aged 19-84 yr; body mass index (BMI) range, 16-47 kg/m2] randomized to treatment with dexamethasone (total dose, 10 μg/4 days) or placebo. Compared with placebo, dexamethasone increased (P = 0.0001) plasma leptin levels by 64-111{\%} above baseline values within 2-4 days. The increases occurred in all ages, showed no sexual dimorphism, and were particularly robust in obese subjects. After dexamethasone treatment, significant interactions were observed between the change in plasma leptin and BMI (P = 0.0001), baseline plasma leptin (P = 0.0006) and plasma dexamethasone levels (P = 0.04), but not age (P = 0.28); an apparent interaction with plasma insulin no longer was significant after controlling for BMI. These results confirm dexamethasone-induced hyperleptinemia in humans and further demonstrate that the response is not defective in obesity.",
author = "Samuel Dagogo-Jack and Gregg Selke and Melson, {Angela K.} and Newcomer, {John W.}",
year = "1997",
month = "10",
day = "13",
doi = "10.1210/jc.82.10.3230",
language = "English (US)",
volume = "82",
pages = "3230--3233",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Robust leptin secretory responses to dexamethasone in obese subjects

AU - Dagogo-Jack, Samuel

AU - Selke, Gregg

AU - Melson, Angela K.

AU - Newcomer, John W.

PY - 1997/10/13

Y1 - 1997/10/13

N2 - Although leptin reverses obesity in rodents, its function and regulation in humans are unknown. Glucocorticoids have been reported to stimulate leptin production in both rodents and humans, but data assessing the effect of obesity on dynamic leptin secretory responses are unavailable. We, therefore, studied 52 lean and obese subjects [20 men and 32 women; aged 19-84 yr; body mass index (BMI) range, 16-47 kg/m2] randomized to treatment with dexamethasone (total dose, 10 μg/4 days) or placebo. Compared with placebo, dexamethasone increased (P = 0.0001) plasma leptin levels by 64-111% above baseline values within 2-4 days. The increases occurred in all ages, showed no sexual dimorphism, and were particularly robust in obese subjects. After dexamethasone treatment, significant interactions were observed between the change in plasma leptin and BMI (P = 0.0001), baseline plasma leptin (P = 0.0006) and plasma dexamethasone levels (P = 0.04), but not age (P = 0.28); an apparent interaction with plasma insulin no longer was significant after controlling for BMI. These results confirm dexamethasone-induced hyperleptinemia in humans and further demonstrate that the response is not defective in obesity.

AB - Although leptin reverses obesity in rodents, its function and regulation in humans are unknown. Glucocorticoids have been reported to stimulate leptin production in both rodents and humans, but data assessing the effect of obesity on dynamic leptin secretory responses are unavailable. We, therefore, studied 52 lean and obese subjects [20 men and 32 women; aged 19-84 yr; body mass index (BMI) range, 16-47 kg/m2] randomized to treatment with dexamethasone (total dose, 10 μg/4 days) or placebo. Compared with placebo, dexamethasone increased (P = 0.0001) plasma leptin levels by 64-111% above baseline values within 2-4 days. The increases occurred in all ages, showed no sexual dimorphism, and were particularly robust in obese subjects. After dexamethasone treatment, significant interactions were observed between the change in plasma leptin and BMI (P = 0.0001), baseline plasma leptin (P = 0.0006) and plasma dexamethasone levels (P = 0.04), but not age (P = 0.28); an apparent interaction with plasma insulin no longer was significant after controlling for BMI. These results confirm dexamethasone-induced hyperleptinemia in humans and further demonstrate that the response is not defective in obesity.

UR - http://www.scopus.com/inward/record.url?scp=0030884983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030884983&partnerID=8YFLogxK

U2 - 10.1210/jc.82.10.3230

DO - 10.1210/jc.82.10.3230

M3 - Article

C2 - 9329344

AN - SCOPUS:0030884983

VL - 82

SP - 3230

EP - 3233

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -